$43.24
+0.12%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$43.50
From 52W high−32.42%
Volume10.30M
Market cap$193.07B
P/E (TTM)10.7x
P/S (TTM)3.8x
Div yield3.46%
Key dataSep 18, 2026
Open
$43.50
From 52W high
−32.42%
Volume
10.30M
Market cap
$193.07B
ValuationView details →
P/E (Fwd)
13.9x
EV/EBITDA
7.5x
P/E (TTM)
10.7x
RSI (14)
41.1
MomentumView details →
1D Return
+0.12%
YTD Return
−15.06%
SummaryUpdated Jun 1, 2026
Novo Nordisk A/S (NYSE:NVO) is a Danish multinational pharmaceutical company founded in 1923 and headquartered in Bagsvaerd, Denmark. The company has evolved from its origins as an insulin manufacturer into a global leader in diabetes care and, more recently, obesity treatment. Novo Nordisk went public in 1981 and has grown to serve over 45 million patients worldwide with diabetes and obesity treatments. The company operates primarily through two business segments: Diabetes and Obesity Care, and Rare Disease, with the former representing the vast majority of its revenue and growth trajectory.
Similar companies
Latest newsMore news →
Novo Nordisk confirmed that the supply of semaglutide is stable across Canada.2d agoThe European Medicines Agency's Committee for Medicinal Products for Human Use endorsed Novo Nordisk's hemophilia A therapy.3d agoNovo Nordisk is introducing Ozempic for diabetes care and Wegovy for weight management in Kenya.6d ago